Faculty Profile, National Health Research Institutes, Taiwan

Faculty Profiles


Tsu-Yi Chao, M.D., D.M.S.

Joint-appointed Investigator
National Institute of Cancer Research
tsuyi@ndmctsgh.edu.tw

EDUCATION

  • Doctorate of Medical Science, Research Institute of Clinical Medicine, NationalDefenseMedicalCenter, Taipei, Taiwan, 1989

  • Bachelor of Medicine, NationalDefenseMedicalCenter, Taipei, Taiwan, 1983

PROFESSIONAL EXPERIENCES

  • Chief and Professor, Division of Hematology/Oncology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan (1997-present)

  • Attending Physician, Division of Hematology/Oncology, Tri-ServiceGeneralHospital, NationalDefenseMedicalCenter, Taipei, Taiwan (1992-1997)

  • Research Fellow, Department of Immunology and Biochemistry Research, Roswell Park Memorial Institute (1987-1789)

  • Resident, Chief Resident, Fellow, Department of Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan (1983~1992)

RESEARCH INTERESTS

Dr. Chao's current research interests focus on clinical trials and translational studies. The clinical trials he involves are about the development of new drugs or strategies in treating cancers and hematological disorders. In translational studies, his major effort is on the development of a novel biochemical marker, i.e. tartrate-resistant acid phosphatase 5b, in the diagnosis and monitoring of metastatic bone disease of breast cancer. He also intends to define the role and search the potential usefulness of tartrate-resistant acid phosphatase 5a in macrophage-related disorders.

RESEARCH ACTIVITIES & ACCOMPLISHMENTS

Dr. Chao began his career in cancer research at Roswell Park Memorial Institute, Buffalo, New York. Subsequently he developed a productive program in the Tri-Service General Hospital using imprint cytology, immunocytochemistry and in situ hybridization for cancer diagnosis as well as immunotherapy for treatment. He has also participated clinical trials involving new drugs on the treatment of various cancers. Additionally, he has cooperated well with Professor Lung Tam Yam and Dr. Anthony Janckilla of the University of Louisville, Kentucky, USA, on the study of tartrate-resistant acid phosphatase (TRACP). Dr. Chao has established the TRACP5a and -5b immunoassays and other related assays in his laboratories. He and his associates demonstrated that the serum TRACP5b activities in Chinese women were not different from those of the Western people. They also found that the serum TRACP5b activity was elevated in the serum of breast cancer patients with bone metastasis but not in those patients without bone metastasis, and the serum TRACP5b activity increased in those patients with extensive bone metastasis only. They found the serum TRACP5b activity may become a good marker for the diagnosis and following up of metastatic bone lesions in those breast cancer patients with extensive bone metastasis. Besides, Dr. Chao and Dr. Janckila have developed a new immunoassay for serum TRACP5a activity and examined the value in normal subjects and found TRACP5a is potentially an inflammatory biomarker in the future.

HONORS & AWARDS

  • Teacher of the year, NationalDefenseUniversity, September 2005.

  • Outstanding Military Physician honored by the Ministry of Defense, Taiwan, 2003.

  • Remarkable physician of Tri-ServiceGeneralHospital, 2001.

  • Scholarship of Biomedical Science for physicianawarded by Academia Sinica, Taiwan, R.O.C., 1994-1995.

SELECTED PUBLICATIONS

  1. Tsai SH, Chen CY, Ku CH, Janckila AJ, Yam LT, Yu JC, Chuang KW and Chao TY*. Correlation between Serum Tartrate-Resistant Acid Phosphatase 5b Activity and A Semi-Quantitative Bone Scintigraphy Index in Breast Cancer Patients with Bone Metastasis. Mayo Clinic Proceedings, 82(8):917-926, 2007. (* = Corresponding Author)

  2. Chuang YC, Ku CH, Chao TY,* Yu JC, Chen M and Lee SH. Tartrate-resistant Acid phosphatase 5b (TRACP5b) Activity is a Useful Bone Marker for Monitoring Bone Metastases in Breast Cancer Patients after Treatment. Cancer Epidemiology, Biomarkers & Prevention, 15(3):424-428, 2006. (* = Corresponding Author)

  3. Chao TY, Lee SH, Chen MM, Neustadt DH, Chaudhry UA, Yam LT and Janckila AJ. Development of immunoassays for serum tartrate-resistant acid phosphatase isoform 5a. Clinica Chimica Acta, 359:132-140, 2005.

  4. Chao TY*, Yu JC, Ku CH, Chen MM, Lee SH, Janckila A and Yam LT.Tartrate-resistant acid phosphatase 5b (TRACP5b) is a useful serum marker for extensive bone metastasis in breast cancer patients.Clinical Cancer Research, 11:544-550, 2005. (* = Corresponding Author)

  5. Chen CJ, Chao TY, Janckila AJ, Cheng SN and Chu DM. Evaluation of the activity of tartrate-resistant acid phosphatase isoforms 5b in normal Chinese children a novel marker for bone growth. Journal of Pediatric Endocrinology and Metabolism, 18:55-62, 2005.

  6. Chao TY*, Lee SH, Chen MJ, Janckila A and Yam LT.Tartrate-resistant acid phosphates 5b (TRACP 5b) as a serum marker of bone metastasis in breast cancer patients.Journal of Biomedical Science, 11:511-516, 2004. (* = Corresponding Author)

  7. Chu P, Chao TY, Lin YF, Janckila AJ and Yam LT. Correlation between histomorphometric parameters of bone resorption and serum type 5b tartrate-resistant acid phosphatase in uremic patients on maintenance hemodialysis.American Journal of Kidney Diseases, 41:1052-1059, 2003.